ILLUMINA VENTURES
ILLUMINA VENTURES
Portfoilio Partner Spotlight
Arbor Biotechnologies Takes the Next Steps in Gene Editing
"This is an exciting direction because it offers opportunities for actual cures," said Illumina Ventures partner Wouter Meuleman. "The ability to correct single-nucleotide variations, or even replace entire genes, will change how we practice medicine."
